Preclinical and clinical development of palbociclib and future perspectives
Clin. transl. oncol. (Print)
; 20(9): 1136-1144, sept. 2018. ilus, tab
Artigo
em Inglês
| IBECS
| ID: ibc-173698
Biblioteca responsável:
ES1.1
Localização: BNCS
ABSTRACT
Cyclin-dependent kinases (CDKs) play a key role in cell cycle regulation, which makes them a clear therapeutic target to interfere with cell division and proliferation in cancer patients. Palbociclib, a specific inhibitor of CDK4/6 with outstanding clinical efficacy data and limited toxicity, has been recently approved for the treatment of hormone receptor (HR)-positive human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, either in combination with an aromatase inhibitor or in combination with fulvestrant in women who have received prior endocrine therapy. This review describes the mechanism of action, preclinical experiences and clinical data of palbociclib, with a special focus on integrating this data with the positioning of palbociclib in the current clinical guidelines for advanced HR-positive/HER2-negative breast cancer. Aspects of the ongoing major studies are also presented, as well as future prospects in the development of palbociclib
RESUMEN
No disponible
Buscar no Google
Coleções:
Bases de dados nacionais
/
Espanha
Base de dados:
IBECS
Assunto principal:
Neoplasias da Mama
/
Inibidor p16 de Quinase Dependente de Ciclina
/
Quinase 4 Dependente de Ciclina
Tipo de estudo:
Guia de prática clínica
Limite:
Animais
/
Humanos
Idioma:
Inglês
Revista:
Clin. transl. oncol. (Print)
Ano de publicação:
2018
Tipo de documento:
Artigo
Instituição/País de afiliação:
Arnau de Vilanova University Hospital/Spain
/
Clinic University Hospital of Valencia/Spain
/
La Fe University Hospital/Spain
/
Pfizer Incorporated/Spain
/
Provincial Hospital of Castellón/Spain
/
Valencian Institute of Oncology/Spain